Enliven Therapeutics (NASDAQ:ELVN) Now Covered by The Goldman Sachs Group

Research analysts at The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a report issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group’s target price indicates a potential upside of 69.72% from the stock’s previous close.

Several other analysts also recently weighed in on the stock. Jones Trading lowered their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a report on Friday, May 16th. HC Wainwright lifted their price objective on Enliven Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $39.60.

Enliven Therapeutics Stock Down 5.6%

ELVN opened at $21.80 on Monday. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.03. The business’s 50 day moving average is $18.45 and its two-hundred day moving average is $20.59. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -11.35 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Equities analysts expect that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the company’s stock in a transaction dated Monday, April 7th. The shares were sold at an average price of $18.04, for a total transaction of $120,272.68. Following the transaction, the chief operating officer now directly owns 316,643 shares in the company, valued at approximately $5,712,239.72. This represents a 2.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $21.33, for a total transaction of $69,322.50. Following the completion of the transaction, the chief financial officer now directly owns 23,000 shares of the company’s stock, valued at approximately $490,590. This trade represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 76,111 shares of company stock worth $1,418,664. Corporate insiders own 25.90% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC raised its holdings in Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after purchasing an additional 1,114 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after buying an additional 2,630 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Enliven Therapeutics in the 1st quarter worth about $60,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Enliven Therapeutics in the 4th quarter worth about $97,000. Finally, BNP Paribas Financial Markets acquired a new stake in Enliven Therapeutics in the 4th quarter valued at about $112,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.